According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1
As the condition progresses, retinal ischaemia (reduced blood supply) triggers the release of vascular endothelial growth factor (VEGF), promoting abnormal new blood vessel formation (neovascularisation)
This leads to common aging signs like fatigue, weakened immunity, slower healing, and age-related diseases
Kacar, A., Oozer, M
Side effects are similar to lower doses but may be more common
potassium overdose can cause fatal heart rhythm problems Pre-treatment screening is essential and should include: Comprehensive medical history and current medication review Kidney and liver function assessment G6PD screening (required before high-dose vitamin C) Relevant lab testing based on individual risk profile Informed consent documenting risks, benefits, evidence gaps, alternatives, and costs During infusion, vital sign monitoring, regular IV site assessment (especially in children and elderly patients), and continuous observation for signs of allergic reaction or fluid overload represent standard practice expectations
